CLINICAL TRIAL: NEW ONSET OF TYPE 1 DIABETES ANTI-CD20 CLINICAL TRIAL

临床试验：新发 1 型糖尿病抗 CD20 临床试验

• 批准号: 7951168
• 负责人: DEBRA R COUNTS
• 金额: $ 0.09万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951168
• 关键词: Cells; Clinical Research; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Immune system; Infusion procedures; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Newly Diagnosed; Pancreas; Patients; Pharmaceutical Preparations; Research; Research Personnel; Resources; Rest; Source; Testing; United States National Institutes of Health; Visit; insulin dependent diabetes mellitus onset; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is testing Rituximab, a drug that alters the immune system in patients newly diagnosed with Type 1 diabetes to see if continued destruction of insulin-producing cells in the pancreas can be halted. Patients will receive the four infusions of Rituximab at another center, and then the rest of the study related visits will take place at UMB GCRC.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 这项研究正在测试利妥昔单抗，一种改变新诊断为1型糖尿病患者免疫系统的药物，看看是否可以停止胰腺中胰岛素产生细胞的持续破坏。患者将在另一个中心接受四次利妥昔单抗输注，然后在UMB GCRC进行其余的研究相关访视。